April 2023 in “Journal of Investigative Dermatology” AL136131.3 slows hair growth by affecting energy processes in hair loss.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
September 2023 in “Journal of Cosmetic Dermatology” Lower vitamin D levels are linked to higher CRP levels in people with a type of hair loss called alopecia areata.
August 2025 in “Journal of Polymer Science” AcD scaffolds improve tissue repair and regeneration by combining stem cells with a supportive matrix.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
October 2014 in “Archives of Disease in Childhood” Growth hormone therapy can improve symptoms and growth in children with Vitamin-D Dependent Rickets Type-2.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
9 citations
,
April 1970 in “Biochemical pharmacology” Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
7 citations
,
January 2016 in “Clinical Hemorheology and Microcirculation” AGA patients have higher heart disease risk.
4 citations
,
May 2018 in “European journal of dermatology/EJD. European journal of dermatology” Fumaric acid esters might help treat alopecia areata, but more research is needed.
37 citations
,
January 2011 in “Annals of Dermatology” ALA-photodynamic therapy helps reduce acne by causing acne cell death and lowering certain skin protein levels.
Sinapic acid and glabridin together help hair growth in androgenetic alopecia.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
August 2018 in “Journal of the American Academy of Dermatology” Calcipotriol may effectively treat hair loss in alopecia areata, working better in children than adults.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
64 citations
,
November 2012 in “EMBO reports” Lamins are vital for cell survival, organ development, and preventing premature aging.
February 2023 in “Clinical, Cosmetic and Investigational Dermatology” Higher leptin and lower vitamin D levels may contribute to male pattern baldness.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
22 citations
,
September 2024 in “Chemical Engineering Journal” A new microneedle patch effectively and safely treats alopecia areata.
October 2002 in “Atherosclerosis Supplements” LDL apheresis lowers inflammation and cardiovascular risk by reducing CRP levels long-term.